Oxford and AstraZeneca begin testing beta variant vaccine

The University of Oxford announced, Sunday, that it has begun injecting volunteers with a vaccine developed with it, AstraZeneca vs. Beta (“South African”) version of
As part of a clinical trial to measure its effectiveness.

It said in a statement that about 2,250 participants will now be recruited from the UK
South Africa, Bij
Brazil and Poland as part of phase II and III human clinical trials. The candidate vaccine uses the same so-called “viral vector” (adenovirus) technology currently used around the world against Covid-19.

Pollution outbreaks in the United Kingdom

Professor Andrew Pollard, Director of the Oxford Vaccine Group, commented: “Testing booster doses of existing vaccines and vaccines against novel variants is important to ensure we are best prepared to stay ahead of the coronavirus pandemic, if needed.”

Interim data from these clinical trials is expected later this year and will be submitted to regulatory authorities for review as part of an accelerated process, the statement said.

In May, the UK government began clinical trials, announced as a world first, on the immune response to a third dose of the Covid-19 vaccine for a recall campaign in the UK, where we are seeing outbreaks of contamination due to the delta variant. (“Indian”).